Trial Profile
A Phase II Clinical Trial of Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 28 Mar 2024
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Adrenocortical carcinoma
- Focus Therapeutic Use
- 22 Mar 2024 Planned End Date changed from 1 Feb 2024 to 1 Feb 2025.
- 22 Mar 2023 Planned End Date changed from 1 Feb 2023 to 1 Feb 2024.
- 03 Mar 2022 Planned End Date changed from 1 Feb 2022 to 1 Feb 2023.